

Supplementary data

Biomarkers of checkpoint inhibitor induced immune-related adverse events – a comprehensive review

Josefien W. Hommes, Rik J. Verheijden, Karijn P.M. Suijkerbuijk, Dörte Hamann

Frontiers in Oncology 2020

	Baseline							EDT*	ΔirAE-baseline**			
	Lim et al. 2019 (41)	S. Khan et al. 2019 (42)	Oyanagi et al. 2019 (43)	Tarhini et al. 2015 (44)	Kurimoto et al. 2020 (45)	Valpione et al. 2018 (37)	Chaput et al. 2017 (28)		Lim et al. 2019 (41)	S. Khan et al. 2019 (42)	Oyanagi et al. 2019 (43)	Tanaka et al. 2017 (38)
sCD40L	Grey		Grey					Grey		Grey		
sCD163												Green
SCF	Grey							Grey				
SCYB16/ CXCL16		Grey							Grey			
SDF-1/ CXCL12	Grey	Grey						Grey	Grey			
TARC/ CCL17	Grey							Grey				
TGF-α	Grey							Grey		Grey		
TGF-β1			Grey	Grey						Grey		
TGF-β2			Grey							Grey		
TGF-β3										Grey		
TNF-α	Grey		Grey	Grey	Grey		Grey	Grey		Grey	Grey	
TNF-β/LT-α	Grey		Grey					Grey		Grey		
TPO	Grey							Grey				
TRAIL	Grey							Grey				
TSLP	Grey							Grey				
VEGF	Grey		Grey	Grey		Grey		Grey		Grey		
VEGF-A			Grey							Grey		
VEGF-C			Grey							Grey		
VEGF-D			Grey							Grey		

*EDT= early during treatment=1-6 weeks after start of therapy

** ΔirAE-baseline= increase/decrease at onset of irAE compared to baseline

† associated with colitis particularly

‡ associated with thyroiditis particularly

¶ associated with psoriasis particularly

Legend

Grey = parameter was analysed but not significantly correlated with irAE

Green = higher/increased in patients with irAE

Orange = lower/decreased in patients with irAE

Yellow = prediction model of multiple parameters